Scientists at Karolinska Institutet have created an engineered antibacterial protein that simultaneously kills antibiotic-resistant bacteria and neutralises the toxins those bacteria release, according to a study published in Molecular Medicine on 14 November 2026. In experimental models of bacterial meningitis, the approach reduced harmful inflammation and neuronal damage, offering a potential new avenue for treating a condition that remains a medical emergency worldwide.

Bacterial meningitis, an infection of the membranes surrounding the brain and spinal cord, can lead to death or lifelong neurological complications. Treatment becomes especially difficult when the infection is caused by antibiotic-resistant strains, and many antibiotics struggle to cross the blood-brain barrier — the protective shield that keeps harmful substances out of the brain but also blocks many drugs.

The Karolinska team, led by corresponding author Federico Iovino, an associate professor at the Department of Neuroscience, turned to a different strategy. They started with an endolysin, a protein enzyme derived from bacteriophages — viruses that infect bacteria. The natural endolysin Cpl-1 was engineered by attaching a peptide that binds to pneumolysin, a major toxin released by Streptococcus pneumoniae (pneumococcus), the leading cause of bacterial meningitis globally.

The resulting chimeric protein was designed to perform two tasks at once: kill the bacteria, especially those resistant to antibiotics, and neutralise the toxin that contributes to inflammation and nerve cell damage. The researchers tested the protein using biochemical and microbiological methods, cell-based experiments, and a mouse model of meningitis.

“With this approach, we wanted to address two important causes of damage at the same time: the bacterial infection itself and the harmful effects of the toxins released by the bacteria,” Iovino said in a statement from Karolinska Institutet.

In mice with meningitis caused by penicillin-resistant pneumococci, the engineered endolysin eliminated the bacteria both in the blood and in the brain. The treatment also reduced the harmful inflammation and neuronal injury associated with toxin release, the researchers reported.

The results provide proof of concept, but this method has not yet been developed into a patient therapy. The team intends to study how to administer it, appropriate dosing and its pharmacological characteristics, and evaluate the technique in models that better mimic real-world medical scenarios. Additionally, they are investigating if this concept could be applied to other drug-resistant bacteria responsible for bloodstream infections, sepsis and diseases of the central nervous system.

“The next step is to optimise the treatment and test it in increasingly translational models of meningitis before it can move towards clinical development,” Iovino said.

Funding for the research came from the Swedish Research Council, Torsten Söderberg Foundation, Novo Nordisk Foundation, Karolinska Institutet, StratNeuro and H.K.H. Crown Princess Lovisa's Association for Child Care. The biochemical analysis was performed jointly with Daniel C Nelson's lab at the University of Maryland's Institute for Bioscience and Biotechnology Research, USA.

For university students studying medicine, microbiology, or neuroscience, this research highlights a promising direction for tackling antibiotic resistance — one of the most pressing global health challenges. The dual-action approach, targeting both the pathogen and its toxic byproducts, could eventually inform new treatments for infections that are increasingly difficult to manage with conventional antibiotics.